Detailed Patient Information
Study: Bridging EBV-Host ImbalaNce to Disease Onset and Progression in Multiple Sclerosis
Posted on October 18, 2024 • 12 minutes • 2374 words
Table of contents
| Study title | Bridging EBV-Host ImbalaNce to Disease Onset and Progression in Multiple Sclerosis |
|---|---|
| Code | |
| Sponsor | VHIR |
| Investigador coordinador | VHIR |
| Investigador principal | Dr. Manuel Comabella |
| Center | HUVH |
| Department | Neurología/Cemcat |
Data Protection Information for Study “Bridging EBV-Host ImbalaNce to Disease Onset and Progression in Multiple Sclerosis**”**
Who is responsible for data processing?
The Fundació Hospital Universitari Vall d’Hebron- Institut de Recerca (VHIR) is the Sponsor of this study and is based at the Vall d’Hebron Hospital (HUVH).
VHIR is a private foundation that wishes to foster, promote and develop scientific and technological research, teaching and the education in the field of the Hospital Universitari Vall d’Hebron (HUVH), the Universidad Autónoma de Barcelona (UAB) and of its spheres of influence.
HUVH is an independent data controller and responsible for ensuring compliance with applicable data protection laws and regulations. It is responsible for all data that appears in the medical history that can lead to identify you.
VHIR is the controller of the data that is collected in this study in a coded/pseudonymized form.
The role of the data controller is to ensure that your information is used correctly. The Sponsor and the Center will comply with data protection regulations:
- Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data.
- Organic Law 3/2018 of December 5, on the Protection of personal data and the guarantee of digital rights
The other joint controllers of this study are:
- DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG (DKFZ) –
established in IM NEUENHEIMER FELD 280, 69120 HEIDELBERG, Germany.
DKFZ will perform experiments with your pseudonymised samples and will analyse the data originating from this. (Please find details under “sample utilization” in the patient information sheet.) The data will be uploaded to a platform hosted on the CNR servers and results of experiments will be shared with the other partners.
- CONSIGLIO NAZIONALE DELLE RICERCHE (CNR), PIC 999979500, established in PIAZZALE ALDO MORO 7, 00185 ROMA, Italy.
The data controller accountable for the processing of the data in the pseudonymised form is the National Research Council of Italy (CNR).
Data analysis will be performed by the Institute of Complex Systems of CNR established in Via dei Taurini 19, 00185 Roma, Italy. Data will be stored and analyzed in the CNR servers located at Area Territoriale di Ricerca Roma 2 - Tor Vergata (ArTov), with a registered office in Via del Fosso del Cavaliere, 100 – 00133 Roma, Italy. ArTov will be responsible solely for managing the server infrastructure and software, without any direct access to the pseudonymised data. All operations on the server infrastructure will be carried out solely on behalf of ISC and in accordance with the instructions provided by the latter, as specified by the ISC-ArTov CNR-internal research Agreement.
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC),
PIC 999988424, with principal place of business at DR MOLEWATERPLEIN 50-60-40, 3015 GE, ROTTERDAM, Netherlands, acting exclusively for and on behalf of its Department of Immunology.
ERASMUS MC will perform experiments with your pseudonymised samples and will analyse the data originating from this. (Please find details under “sample utilization” in the patient information sheet.) The data will be uploaded to a platform hosted on the CNR servers and results of experiments will be shared with the other partners.
- HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT GMBH (HMGU), established in INGOLSTÄDTER LANDSTRAßE 1, 85764 NEUHERBERG, Germany.
HMGU will perform experiments with your pseudonymised samples and will analyse the data originating from this. (Please find details under “sample utilization” in the patient information sheet.) The data will be uploaded to a platform hosted on the CNR servers and results of experiments will be shared with the other partners.
- ISTITUTO SUPERIORE DI SANITÀ (ISS), established in Viale Regina Elena 299, 00161 ROMA, Italy.
ISS will perform experiments with your pseudonymised samples and will analyse the data originating from this. (Please find details under “sample utilization” in the patient information sheet.) The data will be uploaded to a platform hosted on the CNR servers and results of experiments will be shared with the other partners.
- UNIVERSITÀ DEGLI STUDI DI MILANO (UMIL), established in Via Festa Del Perdono 7, 20122 MILANO, Italy.
UMIL will perform experiments with your pseudonymised samples and will analyse the data originating from this. (Please find details under “sample utilization” in the patient information sheet.) The data will be uploaded to a platform hosted on the CNR servers and results of experiments will be shared with the other partners.
- UNIVERSITÄT MÜNSTER (UM), established in SCHLOSSPLATZ 2, 48148 MÜNSTER, Germany.
UM will have access to results of experiments performed with your pseudonymized samples.
- UNIVERSITÀ DEGLI STUDI DI VERONA (UNIVR), (Department of Neurosciences Medicine and Movement Sciences) established in VIA DELL’ARTIGLIERE 8, 37129 VERONA, Italy.
UNIVR will have access to results of experiments performed with your pseudonymized samples.
-
THE EUROPEAN MULTIPLE SCLEROSIS PLATFORM AISBL (E.M.S.P.), established in RUE AUGUSTE LAMBIOTTE 144/8, 1030 BRUXELLES, Belgium.
EMSP will use the findings and outcomes of the project to develop messages to be shared with the public. No personal data which might enable identifying you will be included for this.
-
FONDAZIONE ISTITUTO NAZIONALE DI GENETICA MOLECOLARE INGM (INGM), established in VIA FRANCESCO SFORZA 35, 20122 MILANO, Italy.
INGM will perform experiments with your pseudonymised samples and will analyse the data originating from this. (Please find details under “sample utilization” in the patient information sheet.) The data will be uploaded to a platform hosted on the CNR servers and results of experiments will be shared with the other partners.
- UNIVERSITAT ZURICH (UZH), established in RAMISTRASSE 71, 8006 ZURICH, Switzerland.
UZH will have access to results of experiments performed with your pseudonymized samples.
In the future, the following could become another joint contoller of the study:
The Cyprus Institute of Neurology & Genetics established in P.O.Box 23462, 1683 Nicosia, Cyprus
The Cyprus Institute of Neurology & Genetics will have access to results of experiments performed with your pseudonymized samples if joining the project.
All joint controllers will have access to the results obtained from the experiments performed. This allows the Project to bring together the results to analyze them and create a larger context.
What data will be collected and used, and what is the legal basis for the processing of your personal data?
The Sponsor will not collect more data than necessary for the completion of this study (related to your pathology, the tests performed, and the treatment received).
The following data will be collected during the study: age, sex, and pathology.
The following pseudonymised data will be obtained from the collected samples:
-
Clinical Data: Patient health records and clinical observations.
-
Genetic Data: DNA/RNA genome sequences, including genome sequences, transcriptome, and proteome data.
-
Blood/Serum Data: Single-cell RNA sequences and flow cytometry data.
-
Imaging Data: MRI scans and other imaging data.
-
Laboratory Data: ELISA (enzyme-linked immunosorbent assay) results.
The legal basis for data processing is informed patient consent according to GDPR art. 6 (1) point a), for general personal data, and art. 9(2) point a) for special categories of personal data.
Note: The legitimation on which the processing is based must be documented and accredited)
How will this data be used?
The Sponsor and the other joint controllers will use this data to answer the questions of the study and related research, which are explained in the information sheet that has been provided to you. For the sake of completeness, we hereby recall briefly the aim of this study. The BEHIND-MS project (details available at European Commission Portal ) aims to understand how the Epstein-Barr virus (EBV) promotes the development of Multiple Sclerosis (MS). To achieve this ambitious goal, the project will develop innovative experimental systems to study the interactions between the virus and its host at an unprecedented level of detail.
The Sponsor and the other joint controllers may reuse this data for other research projects related to the disease under study (or related area of interest), always respecting confidentiality and ensuring compliance with current legislation. Your information will only be used in research that has received a favorable report from an Ethics Committee for Research, and in a way that does not contradict the preferences expressed by you in the signed consent. For joint data controllers residing in countries where the law does not require approval by an Ethics Committee, it will be required to obtain a favorable report from the data protection officer or an expert for the terms established in the applicable regulations.
What happens to confidentiality?
At all times, the confidentiality of your data will be maintained. During your participation in the study you will be identified by a code and the Center will not transfer any information that could lead to your identification to the Sponsor, nor to any of the other joint controllers of this study. The list that relates the identification code to the data that identifies you (name, surname, medical history number, …) is kept confidential in your Health Center, and will not leave this Center.
Access to your personally identifiable information will be restricted to the principal investigator of the study/collaborators, health authorities, the Research Ethics Committee and authorized personnel by the Sponsor (study monitors, auditors), when they need it to verify data, study procedures, and compliance with good clinical practice standards; but always maintaining their confidentiality.
Your identity may be revealed in exceptional cases, such as medical emergencies for your health or legal requirements. The processing, communication and transfer of personal data of all participants will be in accordance with the applicable regulations.
How long will your data be stored?
All requested information is necessary to be able to participate in this study and it is mandatory that to be provided, in order to guarantee the correct development of the study. The Center and the Sponsor are obliged to keep the data collected for the study, according to the legal dates established in the regulations: the Sponsor, for for five years after the end of the project, and the Center, for the time necessary to provide you with adequate assistance, up to the end of the project.
The other joint controllers will keep the data, collected during this study in a pseudonymized form, for 5 years after the ending of the project. The pseudonymised data will be retained on the ArTov server
What rights do I have?
Regarding your data, you have the following rights:
You can ask at any time what data is being stored (right of access), who is using it and for what purpose; you can request a copy of your personal data for your own use. You can request to receive a copy of the personal data provided by you to transmit it to other people (portability). You can correct the personal data provided by you (right of rectification) and limit the use of data that is incorrect (right of rectification and deletion). You can object to the use of your personal data or restrict it (right to object).
In relation to the rights over your personal data, we remind you that there are some limitations in order to guarantee the validity of the research and comply with the legal duties of the Sponsor and the drug authorization requirements. The data collected up to that time cannot be deleted even if you stop participating in the study or even if you withdraw your consent to the data processing. Likewise, you may have limited the right of access to the data (for example, until the study ends). You will also have the right to withdraw your consent to the processing of data, however, such withdrawal could determine your cessation of participation in the study. For the same reason, if you withdraw from the study, we will keep the information about you that has already been collected up to that time. To protect your rights, we will use the least amount of information possible.
We also inform you of your right to file a claim with the Data Protection Agency against any action by the Sponsor,the Center or by any other data controllers that you consider violates your rights in terms of data protection. If you wish, you can contact the data protection officer of your Hospital for the study, or contact the data protection officer of any of the joint controllers specified in the section “Who do I contact?”.
Will my data be shared and transferred?
Yes. Only the data collected for the study (age, sex, and pathology) will be transmitted to third parties. In no case will they contain information such as name and surname, initials, address, or social security number.
The Sponsor may transfer or share your data with other researchers within or outside the European Economic Area. In any case, the recipients of the data will not have access to the code that allows your data to be linked to you; only your doctor or the Hospital staff have access to this code.
How will the results be communicated?
The Sponsor and joint controllers will publish the results of the study, preferably in scientific journals, congresses, etc. The anonymity of the participants in the study will be maintained at all times.
Who do I contact?
Contact details of Principal Investigator:
If you need more information about this study, you can contact the researcher in charge:
Principal Investigator: Dr. Manuel Comabella
Departament of neuroinmunología clínica, Institut de Recerca (VHIR)
Centre d’ Esclerosi múltiple de Catalunya (Cemcat)
Hospital Vall d’Hebron,
Ps. Vall d’Hebron 149-151, 08035-Barcelona
Tel: 932746834